JP6812436B2 - 抗ウイルス薬およびウイルス感染症の治療方法 - Google Patents

抗ウイルス薬およびウイルス感染症の治療方法 Download PDF

Info

Publication number
JP6812436B2
JP6812436B2 JP2018528557A JP2018528557A JP6812436B2 JP 6812436 B2 JP6812436 B2 JP 6812436B2 JP 2018528557 A JP2018528557 A JP 2018528557A JP 2018528557 A JP2018528557 A JP 2018528557A JP 6812436 B2 JP6812436 B2 JP 6812436B2
Authority
JP
Japan
Prior art keywords
copolymer
molecular weight
composition according
acrolein
daltons
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018528557A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019510731A5 (https=
JP2019510731A (ja
Inventor
ジョン ハミルトン メルローズ グラハム
ジョン ハミルトン メルローズ グラハム
ケリン デリッツィア ミシェル
ケリン デリッツィア ミシェル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Recce Ltd
Original Assignee
Recce Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016900595A external-priority patent/AU2016900595A0/en
Application filed by Recce Ltd filed Critical Recce Ltd
Publication of JP2019510731A publication Critical patent/JP2019510731A/ja
Publication of JP2019510731A5 publication Critical patent/JP2019510731A5/ja
Application granted granted Critical
Publication of JP6812436B2 publication Critical patent/JP6812436B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • AIDS & HIV (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2018528557A 2016-02-19 2017-02-17 抗ウイルス薬およびウイルス感染症の治療方法 Active JP6812436B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2016900595 2016-02-19
AU2016900595A AU2016900595A0 (en) 2016-02-19 Method for treatment of cancer or viral infection
AU2016902715 2016-07-11
AU2016902715A AU2016902715A0 (en) 2016-07-11 Method for treatment of cancer or viral infection
PCT/AU2017/050139 WO2017139849A1 (en) 2016-02-19 2017-02-17 Anti-virus agent and method for treatment of viral infection

Publications (3)

Publication Number Publication Date
JP2019510731A JP2019510731A (ja) 2019-04-18
JP2019510731A5 JP2019510731A5 (https=) 2020-02-06
JP6812436B2 true JP6812436B2 (ja) 2021-01-13

Family

ID=59624666

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018528557A Active JP6812436B2 (ja) 2016-02-19 2017-02-17 抗ウイルス薬およびウイルス感染症の治療方法

Country Status (7)

Country Link
US (2) US11045491B2 (https=)
EP (1) EP3416656B1 (https=)
JP (1) JP6812436B2 (https=)
CN (1) CN108472311B (https=)
AU (2) AU2017220391B2 (https=)
ES (1) ES2867453T3 (https=)
WO (1) WO2017139849A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115397880B (zh) * 2020-01-31 2025-06-17 瑞克制药有限公司 用于制备生物活性共聚物的工艺
US20210330700A1 (en) * 2020-04-23 2021-10-28 Johnson & Johnson Consumer Inc. Methods and compositions for inhibiting influenza viruses using low molecular weight hydrophobically modified polymers and polyalkylene glycols
WO2025129262A1 (en) * 2023-12-21 2025-06-26 Gramele Industrial Holdings Pty Ltd Methods of ameliorating microbial growth

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3278126D1 (en) * 1981-09-30 1988-03-31 Nat Res Dev Sustained release compositions
CN87108390A (zh) * 1986-12-23 1988-09-21 生物聚合物有限公司 抑制生物和杀生物的组合物
NZ222979A (en) 1986-12-23 1990-09-26 Biopolymers Ltd Polymeric biocidal or biostatic compounds and compositions
AUPN327695A0 (en) 1995-05-30 1995-06-22 Chemeq Pty. Limited Chemotherapeutic compositions
US6060571A (en) 1996-02-22 2000-05-09 Degussa Aktiengesellschaft Acrolein-releasing copolymers
EP0792895B1 (de) * 1996-02-22 2001-05-16 Degussa AG Acrolein freisetzende Copolymere
US6060235A (en) 1997-09-19 2000-05-09 Geltex Pharmaceuticals, Inc. Antiviral polymers comprising acid functional groups and hydrophobic groups
US7629002B2 (en) 2000-02-16 2009-12-08 Chemeq Ltd. Antimicrobial polymeric compositions and method of treatment using them
AU754178B2 (en) 2000-02-16 2002-11-07 Chemeq Ltd Antimicrobial polymeric compositions
CN1617733B (zh) * 2002-01-18 2010-04-07 凯米克有限公司 胃肠疾病的治疗方法和用于其中的聚合物组合物
AUPS327102A0 (en) * 2002-06-28 2002-07-18 Chemeq Ltd Method of treatment or prophylaxis of gastrointestinal diseases
BRPI0416298A (pt) * 2003-11-06 2007-01-23 Chemeq Ltd método para manufatura de poliacroleìna
ES2556732T3 (es) * 2007-11-07 2016-01-19 Recce Limited Polímeros anti-microbianos y sus composiciones
EP2186521A1 (en) * 2008-11-14 2010-05-19 Mergemeier Steffen Compositons for the treatment and prevention of diseases involving bacterial, viral and fungal pathogens and fragments thereof with polyvinylpyrrolidone and/or polyvinylpolypyrrolidone as therapeutically active compound
AU2010100972A4 (en) * 2009-10-19 2010-10-07 Chemeq Ltd Topical antimicrobial compositions
WO2011047420A1 (en) * 2009-10-19 2011-04-28 Chemeq Ltd Cosmetic compositions
US20190202908A1 (en) * 2014-04-15 2019-07-04 President And Fellows Of Harvard College Bi-specific agents
JP6605602B2 (ja) * 2014-11-18 2019-11-13 レッセ ファーマシューティカルズ リミテッド 細菌感染の治療のためのコポリマーおよび方法

Also Published As

Publication number Publication date
AU2017220391B2 (en) 2023-01-19
AU2023201883B2 (en) 2024-08-08
HK1254547A1 (zh) 2019-07-19
CN108472311B (zh) 2021-06-22
EP3416656A1 (en) 2018-12-26
WO2017139849A1 (en) 2017-08-24
US20210275573A1 (en) 2021-09-09
US20180338994A1 (en) 2018-11-29
US11045491B2 (en) 2021-06-29
AU2023201883A1 (en) 2023-05-04
CN108472311A (zh) 2018-08-31
EP3416656B1 (en) 2021-04-21
EP3416656A4 (en) 2019-11-13
AU2017220391A1 (en) 2018-05-17
ES2867453T3 (es) 2021-10-20
JP2019510731A (ja) 2019-04-18

Similar Documents

Publication Publication Date Title
AU2023201883B2 (en) Anti-virus agent and method for treatment of viral infection
JP7681000B2 (ja) アフリカ豚熱を治療するための薬物組成物及びその使用
CN113244212B (zh) 黄芩素在制备预防和/或治疗新型冠状病毒感染疾病的药物中的应用
CN115867268A (zh) 用于治疗或预防病毒性疾病的维多氟拉迪莫
WO2021207399A1 (en) Hydrolysable tannins for use in mitigating acute respiratory distress syndrome
CN120837488B (zh) 金合欢素在制备防治白斑综合征药物中的应用
Jiang et al. Curcumin activates the JAK-STAT signaling pathway to enhance the innate immune response against porcine epidemic diarrhea virus infection in vivo and in vitro
JP6605602B2 (ja) 細菌感染の治療のためのコポリマーおよび方法
CN116322681A (zh) 利拉鲁肽和吉非替尼的抗病毒用途
US20220401469A1 (en) Process for preparation of biologically active copolymer
CN108014129B (zh) 铁离子在抑制rna病毒中的应用
HK1254547B (zh) 抗病毒剂和治疗病毒感染的方法
CN112691094B (zh) 防治病毒的新型化合物及其应用
AU2021219576A1 (en) Method of treatment using meta-arsenite
WO2022049541A1 (en) Antiviral silencing rna molecules, chemically modified antiviral silencing rna molecules with enhanced cell penetrating abilities, pharmaceutical compositions comprising same and uses thereof for treatment of viral infections
CN113398120A (zh) 阿比多尔在制备预防或治疗SARS-CoV-2病毒所致疾病的药物中的用途
WO2015027056A1 (en) NOVEL METHOD OF REDUCING ANTIGENIC DRIFT OR REASSORTMENT OF VIRUSES IN A HOST ANIMAL USING α- INTERFERON
JP2014084306A (ja) ポリアルキレンイミン誘導体を含むウイルス感染症治療薬

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20180601

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191219

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201005

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201013

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201104

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201117

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201216

R150 Certificate of patent or registration of utility model

Ref document number: 6812436

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250